Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature

Journal of Dermatological Case Reports

Volumn 9, Issue 3, 2015, Pages 71-75

  Chimenti, Maria Sole ^a   Talamonti, Marina ^a   Novelli, Lucia ^a   Teoli, Miriam ^a   Galluzzo, Marco ^a   Triggianese, Paola ^a   Perricone, Roberto ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Autoimmune diseases; Psoriasis; Rheumatoid arthritis; Sj gren s syndrome; Ustekinumab

Indexed keywords

AZATHIOPRINE; HYDROXYCHLOROQUINE; METHYLPREDNISOLONE; PREDNISONE; USTEKINUMAB;

ADULT; ARTHRALGIA; ARTICLE; BONE EROSION; CASE REPORT; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; LONG TERM CARE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PSORIASIS; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYNOVITIS; TUBERCULOSIS;

EID: 84957865071     PISSN: None     EISSN: 18987249     Source Type: Journal    
DOI: 10.3315/jdcr.2015.1207     Document Type: Article

References (18)

1. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005; 6: 1123-1132. PMID: 16200070.
2. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005; 6: 1133-1141. PMID: 16200068.
3. Ambrosi A, Espinosa A, Wahren-Herlenius M. IL-17: a new actor in IFN-driven systemic autoimmune diseases. Eur J Immunol. 2012; 42: 2274-2284. PMID: 22949326.
4. ChabaudM, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine. 2000; 12: 1092-1099. PMID: 10880256.
5. Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis. 2002; 61: 704-713. PMID: 12117676.
6. Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, SatheM, Grein J, Gorman DM, Bowman EP, McClanahan TK, Yearley JH, Eberl G, Buckley CD, Kastelein RA, Pierce RH, Laface DM, Cua DJ. IL23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8-entheseal resident T cells. Nat Med. 2012; 18: 1069-1076. PMID: 22772566.
7. Chan JR, BlumenscheinW, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, Lucian L, Geissler R, Brodie S, Kimball AB, Gorman DM, Smith K, deWaal Malefyt R, Kastelein RA, McClanahan TK, Bowman EP. IL23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependentmechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006; 203: 2577-2587. PMID: 17074928.
8. Bartlett BL, Tyring SK. Ustekinumab for chronic plaque psoriasis. Lancet. 2008; 371: 1639-1640. PMID: 18486724.
9. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009; 373: 633-640. PMID: 19217154.
10. Adams DR, Buckel T, Sceppa JA. Infliximab associated new-onset psoriasis. J Drugs Dermatol. 2006; 5: 178-179. PMID: 16485887.
11. Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E, Papay P, Allez M, Cosnes J, Cortot A, Laharie D, Reimund JM, Lemann M, Delaporte E, Colombel JF; Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010; 8: 1048-1055. PMID: 20728573.
12. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012; 9: 496-503. PMID: 22751454.
13. HarrisonMJ, DixonWG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DP; British Society for Rheumatology Biologics Register Control Centre Consortium; BSRBR. Rates of newonset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009; 68: 209-215. PMID: 18385277.
14. Fiorino G, Danese S, Pariente B, AllezM. Paradoxical immunemediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev. 2014; 13: 15-19. PMID: 23777821.
15. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF-IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A. 2005; 102: 3372-3377. PMID: 15728381.
16. Ma HL, Napierata L, Stedman N, Benoit S, Collins M, Nickerson-Nutter C, Young DA. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum. 2010; 62: 430-440. PMID: 20112373.
17. Grine L, Dejager L, Libert C, Vandenbroucke RE. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17. Cytokine Growth Factor Rev. 2015; 26: 25-33. PMID: 25434285.
18. Novelli L, ChimentiMS, Chiricozzi A, Perricone R. The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies. Autoimmun Rev. 2014; 13: 64-69. PMID: 24021172.